Oruka Therapeutics is a clinical-stage biotechnology company founded in 2024 via merger with a shell entity, focused on developing potentially best-in-class monoclonal antibodies targeting IL-23 and IL-17 pathways for psoriasis and other inflammatory diseases, with strong analyst support and substantial cash runway but no approved products or revenue to date.
Key Facts: The company completed its reverse merger and began trading as ORKA on September 3, 2024. The 52-week trading range (as of mid-July 2026 data) was approximately $12.84 (low) to $97.78 (high). The stock has shown significant volatility typical of early-stage biotechs.
| Period | Approximate Return | Comparison to S&P 500 |
|---|---|---|
| YTD (through mid-July 2026) | +205.84% | S&P 500: +8.94% |
| 1-Year | +503.52% | S&P 500: +18.43% |
| Since Listing (Sep 2024) | Substantial gains from post-merger levels | Outperformed broader market significantly |
Additional Performance Notes: High trading volumes on news days (e.g., trial data, financings). Average daily volume around 1.8M shares in recent periods.
Historical Stock Data (Yahoo Finance) | Company IR Stock Chart | Nasdaq Historical Quotes
Key Facts (from quarterly reports as of Q1 2026 and earlier 2025 releases):
| Metric | Recent Value | Notes |
|---|---|---|
| Market Cap | ~5.59B (mid-July 2026 context) | Fact; fluctuates with stock price |
| Net Income (TTM approx.) | -$94.19M | Fact from aggregated reports |
| EPS (TTM) | -$1.93 | Fact |
| Cash Position | $350M–$500M range (2025-2026 quarters) | Fact; runway supports operations to potential BLA |
| Shares Outstanding | ~60.31M | Fact |
Interpretation: The cash position and recent financings provide a multi-year runway, potentially funding ORKA-001 toward BLA filing and ORKA-002 advancement. This is viewed positively by analysts for a pre-revenue biotech.
Uncertainty: Actual cash burn may increase with clinical trial expansion; future dilution from additional offerings possible.
Company IR Earnings Releases | Yahoo Finance Financials | Nasdaq Financials
Consensus: Strong Buy / Moderate Buy across major firms (100% Buy ratings in several summaries; 17+ Buy ratings with 0 Hold/Sell in recent aggregates). Average price targets range from ~$78 to $144+ (highs up to $200, lows ~$20 from earlier coverage).
| Analyst/Firm | Rating | Price Target | Date (approx.) | Action |
|---|---|---|---|---|
| BTIG | Buy | $151 | July 13, 2026 | Reiterated |
| UBS | Buy | $130 | July 2026 | Maintained |
| H.C. Wainwright | Buy | $120 | June 23, 2026 | Reiterated |
| Stifel Nicolaus | Buy | Raised (specific not detailed) | June 29, 2026 | Reiterated |
| Barclays (earlier) | Buy | $160 (high) | April 2026 | — |
| Wolfe Research (earlier) | — | $20 (low) | Feb 2025 | — |
Interpretation: Bullish sentiment driven by positive early clinical data (e.g., PASI responses), partnerships (Halozyme), and funding. Targets imply significant upside potential from mid-2026 levels.
Uncertainty: Analyst ratings and targets are opinions based on models/assumptions about trial success and market size; they can change rapidly with new data and do not guarantee stock performance.
TipRanks Analyst Forecasts | Yahoo Analyst Ratings | MarketBeat Consensus
Key Facts: As a clinical-stage company with no approved products, Oruka has no current commercial customers or revenue-generating sales. Target patient population includes the ~125 million people worldwide with psoriasis (one-third of whom may develop psoriatic arthritis), plus broader I&I indications. Future customers would include patients, dermatologists/rheumatologists, healthcare providers, and payers (insurers/governments) upon potential approval and commercialization.
Interpretation: Success would depend on demonstrating superior efficacy (high complete clearance rates) and convenience (infrequent dosing, e.g., annual) versus existing therapies.
Uncertainty: Commercial adoption, pricing/reimbursement, and market penetration are highly uncertain and depend on pivotal trial results, regulatory approval, and competitive landscape.
Key Facts: Competes in the psoriasis and I&I biologics space. Direct peers are other clinical-stage biotechs developing IL-23/IL-17 or related pathway inhibitors. Established therapies from big pharma include IL-23 inhibitors (e.g., Skyrizi, Tremfya) and IL-17 inhibitors (e.g., Cosentyx, Taltz).
| Competitor | Ticker | Focus/Stage | Notes |
|---|---|---|---|
| Apogee Therapeutics | APGE | Psoriasis/I&I biologics | Similar stage; recent acquisition news noted in coverage |
| Spyre Therapeutics | SYRE | Psoriasis/I&I | Clinical-stage peer |
| Enliven Therapeutics | ELVN | Biologics/oncology overlap | Peer in innovative modalities |
| Tyra Biosciences | TYRA | Precision oncology/I&I | Smaller cap peer |
| AbbVie, Janssen, Novartis, Eli Lilly (Big Pharma) | ABBV, JNJ, NVS, LLY | Approved IL-23/IL-17 therapies | Market leaders; Oruka aims to differentiate on dosing/efficacy |
Interpretation: Oruka positions its candidates as potentially best-in-class with engineered improvements (via Paragon) for durability and convenience. Recent Halozyme collaboration for Hypercon™ technology aims to enhance ORKA-001.
Uncertainty: Head-to-head data is limited; differentiation remains to be proven in larger trials. Market share capture against entrenched competitors is uncertain.
Company Website & Pipeline | Yahoo Company Profile | MarketBeat Competitors
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Menlo Park, California, developing novel monoclonal antibody therapeutics for plaque psoriasis (PsO) and other inflammatory & immunology (I&I) indications. Pipeline includes ORKA-001 (IL-23 p19 subunit, Phase 2a), ORKA-002 (IL-17A/F, Phase 2), ORKA-003 (undisclosed), and potential combinations. Mission emphasizes high rates of complete disease clearance with infrequent dosing (potentially 1-2x/year).
Pre-merger Oruka founded February 2024 by Fairmount Funds Management (Peter Harwin) to hold IP from Paragon Therapeutics (founded 2021 as discovery engine). Merged with ARCA biopharma (former ticker ABIO, a shell) on September 3, 2024, with concurrent $275M private placement. Shares began trading as ORKA on Nasdaq Global Market. Subsequent financings and data readouts followed. Leadership includes CEO Lawrence Klein, PhD; Chairman Samarth Kulkarni, PhD (CRISPR Tx).
Company Investor Relations | Yahoo Recent News | Company Who We Are